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Vitamin D and diabetic 
nephropathy
Animal models of diabetes reproduce 
many of the human phenomena. But in 
db/db mice, a popular model, it seems 
that diabetic renal disease is much 
milder than it is in humans. In a paper 
in this issue, Wang et al. propose that 
these mice might have protective genes 
that reduce diabetic nephropathy. By 
examining the expression of genes 
in glomeruli of db/db mice with 
microarrays, they discovered that a large 
number of genes that mediate calcium 
signaling were elevated. Some of these 
genes included those targeted by the 
vitamin D receptor. One such gene, 
the 1α-hydroxylase gene that is usually 
thought to be in proximal tubule, was 
found to be expressed in the podocyte. 
Remarkably, serum vitamin D3 and 
urinary calcium excretion levels were 
elevated in the db/db mice. In podocytes 
cultured in the presence of high 
glucose, the authors found an increased 
expression of vitamin D receptor as well 
as its targets. High glucose also led to 
enhanced production of fi bronectin, a 
fi nding that might underlie glomerular 
sclerosis. However, treatment of these 
podocytes with 1,25-dihydroxyvitamin 
D3 prevented the increase in fi bronectin. 
In addition to providing a beginning 
explanation for the mild renal 
disease in db/db mice, these studies 
have wider implications in that they 
buttress the increasing evidence of 
the role of vitamin D and its targets in 
infl ammation and fi brosis. See page 882.
Memory T cells 
in Wegener’s 
granulomatosis
Th e immune mechanisms that 
mediate Wegener’s granulomatosis 
remain obscure. In order to test the 
eff ector limb of the immune system, 
Abdulahad et al. examined the 
distribution of peripheral naive and 
memory T lymphocytes in this disease 
in patients with active disease, in those 
who were deemed to be in remission, 
and in healthy controls. Th e T cells 
were classifi ed into their component 
parts with the use of fl uorescence-
activated cell sorter analysis and the 
binding of the variety of antibodies 
that defi ne T-regulatory cells, Th 1 
and Th 2, as well as analysis of naive 
and memory CD4 and CD8 T cells. 
Patients who were in remission had a 
higher abundance of eff ector memory 
T cells but a reduced number of 
the naive T-cell population (results 
comparable to those of similar studies 
done with age-matched normal human 
controls). Remarkably, there was an 
increase in the Th 2 eff ector memory 
T cells during remission. Th ese cells 
have a higher level of expression of 
chemokine receptors, suggesting that 
when they enter an infl ammatory 
milieu they are able to respond 
actively. Th e puzzle is how patients 
in clinical remission could exhibit 
such an abundance of these eff ector 
cells. Th e authors argue that the high 
number of these cells is the likely 
cause of relapse in these patients, a 
phenomenon that is all too frequent. 
See page 938.
Improvement in 
cognition in nocturnal 
dialysis
Th e complex syndrome of uremia includes 
many neurological, psychiatric, and cog-
nitive components. Patients with cognitive 
impairment usually improve with dialysis, 
although the eff ect is only partial. It is not 
known whether partial improvement is 
due to inadequate dialysis or the retention 
of non-dialyzable ‘toxins.’ Previous studies 
had shown that nocturnal daily hemodi-
alysis markedly improved quality of life 
and improved cardiac function, periph-
eral vascular disease, and other manifesta-
tions of uremia in these patients. As they 
report in a new article, Jassal et al. tested 
the cognitive function of patients before 
and after 6 months of nocturnal daily 
dialysis. Several spheres of brain function 
were studied; these included attention, 
working memory, learning effi  ciency, and 
processing speed, as well as more subjec-
tive measures of depression and cogni-
tive function. Over the 6-month period, 
there was a modest reduction in cognitive 
symptoms, improvement in psychomo-
tor effi  ciency and processing speed, and 
signifi cant improvement in attention and 
working memory. All these changes were 
statistically signifi cant in comparison with 
the tests done at the beginning of dialysis. 
Although it would have been nice to com-
pare these results with those obtained in 
patients undergoing more traditional dial-
ysis prescriptions, these results add to the 
already increasing literature that suggests 
that nocturnal daily dialysis is benefi cial 
in ameliorating the complex manifesta-
tions of uremia. See page 956.
